Wang Y Y, Teicher B A, Shea T C, Holden S A, Rosbe K W, al-Achi A, Henner W D
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
Cancer Res. 1989 Nov 15;49(22):6185-92.
A panel of four cell sublines, each selected for resistance to a different antineoplastic agent, has been developed from a human malignant melanoma cell line G3361. Following repeated exposure to escalating doses of the drug of interest, cloned sublines were developed that are 9-fold resistant to cisplatin (G3361/CP), 11-fold resistant to 4-hydroxyperoxy-cyclophosphamide (4-HC) (G3361/HC), 4-fold resistant to carmustine (BCNU) (G3361/BCNU), and 4-fold resistant to melphalan (G3361/PAM). The cross-resistance of each resistant cell line was determined for cisplatin, BCNU, 4-HC, melphalan, carboplatin, nitrogen mustard, and Adriamycin. In general, the alkylating agent-resistant cell lines were specifically resistant to the drug used for selection with the exception of the G3361/CP line, which was greater than 10-fold resistant to the cisplatin analogue carboplatin, 4-fold resistant to 4-HC, and slightly (1.5-fold) resistant to melphalan, and the G3361/BCNU line, which was slightly (1.8-fold) resistant to melphalan. Collateral sensitivity of the G3361/CP, G3361/PAM, and G3361/4HC lines to killing by BCNU was also observed. Glutathione-S-transferase activity was elevated in each of the alkylating agent-resistant cell lines by 3- to 5-fold with chlorodinitrobenzene substrate. On Western blotting, the glutathione-S-transferase-pi (GST-pi) isoenzyme protein was elevated in the resistant cells by 3- to 5-fold. A complementary DNA (pTS4-10) coding for GST-pi has been cloned from a lambda gt11 library, sequenced, and used as a probe to determine the relative levels of GST-pi mRNA in the alkylating agent-resistant cell lines. GST-pi mRNA levels were elevated (8- to 15-fold) in the resistant cell lines, indicating that the GST-pi increases were mediated through an increase in mRNA levels. GST-pi elevations are a frequent event in cells selected for alkylating agent resistance, and in some cases, of multiple drug resistance. However, the lack of cross-resistance among cell lines selected for resistance to different alkylating agents, all of which have elevated GST-pi levels, indicates that increased levels of GST-pi cannot be the predominate mechanism for resistance to the tested drugs in these cell lines.
已从人恶性黑色素瘤细胞系G3361中培育出一组四个细胞亚系,每个亚系都对一种不同的抗肿瘤药物具有抗性。在反复暴露于递增剂量的目标药物后,培育出了对顺铂具有9倍抗性(G3361/CP)、对4 - 羟基过氧环磷酰胺(4 - HC)具有11倍抗性(G3361/HC)、对卡莫司汀(BCNU)具有4倍抗性(G3361/BCNU)以及对美法仑具有4倍抗性(G3361/PAM)的克隆亚系。测定了每个抗性细胞系对顺铂、BCNU、4 - HC、美法仑、卡铂、氮芥和阿霉素的交叉抗性。一般来说,除了G3361/CP细胞系外,对烷化剂具有抗性的细胞系对用于筛选的药物具有特异性抗性,G3361/CP细胞系对顺铂类似物卡铂具有大于10倍的抗性,对4 - HC具有4倍抗性,对美法仑具有轻微(1.5倍)抗性;G3361/BCNU细胞系对美法仑具有轻微(1.8倍)抗性。还观察到G3361/CP、G3361/PAM和G3361/4HC细胞系对BCNU杀伤具有协同敏感性。在以氯二硝基苯为底物时,每个对烷化剂具有抗性的细胞系中的谷胱甘肽 - S - 转移酶活性均升高了3至5倍。在蛋白质印迹法中,抗性细胞中的谷胱甘肽 - S - 转移酶 - π(GST - π)同工酶蛋白升高了3至5倍。已从λgt11文库中克隆出编码GST - π的互补DNA(pTS4 - 10),进行了测序,并用作探针来测定对烷化剂具有抗性的细胞系中GST - π mRNA的相对水平。抗性细胞系中的GST - π mRNA水平升高(8至15倍),表明GST - π的增加是通过mRNA水平的增加介导的。GST - π升高在选择对烷化剂具有抗性的细胞以及某些情况下对多种药物具有抗性的细胞中是常见事件。然而,在选择对不同烷化剂具有抗性的细胞系中缺乏交叉抗性,所有这些细胞系的GST - π水平均升高,这表明GST - π水平的升高不能成为这些细胞系对测试药物产生抗性的主要机制。